Replies to post #128590 on Biotech Values

[DewDiligence]

I just wonder if maybe Roche has an eye on ACHN as well, if they're on the HCV prowl. They could pair ANA598 with a potentially better PI (ACH-1625 or ACH-2684) and/or one of ACHN's NS5A inhibitors down the road with an acquisition of ACHN.

If that were the plan, wouldn’t it make more sense for Roche to move on ACHN first and then go after ANDS later?